{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:39:30Z","timestamp":1785469170613,"version":"3.56.0"},"reference-count":28,"publisher":"Informa UK Limited","issue":"5","funder":[{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"crossref","award":["EMA\/2018\/18\/PE SC01 & SC02"],"award-info":[{"award-number":["EMA\/2018\/18\/PE SC01 & SC02"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Acta Clinica Belgica"],"published-print":{"date-parts":[[2022,9,3]]},"DOI":"10.1080\/17843286.2021.1983708","type":"journal-article","created":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T13:43:51Z","timestamp":1632663831000},"page":"815-822","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["The implementation of risk minimization measures to prevent teratogenic pregnancy outcomes related to oral retinoid and valproate use in Belgium"],"prefix":"10.1080","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4815-9067","authenticated-orcid":false,"given":"Xander","family":"Bertels","sequence":"first","affiliation":[{"name":"Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1848-208X","authenticated-orcid":false,"given":"Els","family":"Mehuys","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2582-5044","authenticated-orcid":false,"given":"Koen","family":"Boussery","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-4363","authenticated-orcid":false,"given":"Lies","family":"Lahousse","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,9,26]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2006.00082.x"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2007.11.005"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2009.01182.x"},{"issue":"1","key":"cit0004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/tog.12075","volume":"16","author":"Browne H","year":"2014","journal-title":"Obstet Gynaecol"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198510033131401"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2008.04.022"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30107-8"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70323-X"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2009.02.014"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.4.2.345"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0803531"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02668.x"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2009.176990"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-304270"},{"key":"cit0015","unstructured":"European Medicine A. Isotretinoin - Art 31 referral - EMEA\/CPMP\/2811\/03 - Annex I, II, III. 2003."},{"key":"cit0016","unstructured":"European Medicine A. Valproate and related substances - Art 31 referral - EMEA\/H\/A-31\/1387 - Annex II. 2015. p. 34\u201339."},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3200"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.745850"},{"issue":"10","key":"cit0019","volume":"38","author":"Veyries ML","year":"2015","journal-title":"Drug Saf"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.151243"},{"key":"cit0021","unstructured":"European Medicine A. EMA\/254364\/2018 - Pharmacovigilance Risk Assessment Committe (PRAC) assessment report: retinoids containing medicinal products. 2018."},{"key":"cit0022","unstructured":"European Medicine A. EMA\/198940\/2018 - Pharmacovigilance Risk Assessment Committee (PRAC) assessment report: medicinal products containing substances related to valproate. 2018."},{"key":"cit0023","unstructured":"European Medicine A. Valproate - Art 31 referral - EMEA\/H-A31\/1454 - Annex III. 2018."},{"key":"cit0024","unstructured":"European Medicine A. Retinoid - Art 31 referral - EMEA\/H\/A-31\/1446 - Annex III. 2018."},{"key":"cit0025","unstructured":"FAMHP. Valproate: knowledge of the risks associated with taking during pregnancy - Results of the 2018 FAMHP survey. 2018 [cited 2021 Mar 04]. Available from: https:\/\/www.famhp.be\/en\/news\/valproate_knowledge_of_the_risks_associated_with_taking_during_pregnancy_results_of_the_2018"},{"key":"cit0026","unstructured":"FAMHP. Approved RMA materials 2021. [cited 2021 Aug 30]. Available from: https:\/\/www.fagg-afmps.be\/nl\/MENSELIJK_gebruik\/geneesmiddelen\/geneesmiddelen\/goed_gebruik_geneesmiddel\/risicobeheerprogramma\/rma"},{"issue":"2","key":"cit0027","first-page":"121","volume":"36","author":"Picavet C","year":"2012","journal-title":"Tijdschrift voor Seksuologie"},{"key":"cit0028","unstructured":"Erens B, McManus S, Prescott A, et al. National survey of sexual attitudes and lifestyles II reference tables and summary report with National Survey of Sexual Attitudes and Lifestyles II. 2003. p. 33-33."}],"container-title":["Acta Clinica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17843286.2021.1983708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T10:18:31Z","timestamp":1662459511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17843286.2021.1983708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,26]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9,3]]}},"alternative-id":["10.1080\/17843286.2021.1983708"],"URL":"https:\/\/doi.org\/10.1080\/17843286.2021.1983708","relation":{},"ISSN":["1784-3286","2295-3337"],"issn-type":[{"value":"1784-3286","type":"print"},{"value":"2295-3337","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yacb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yacb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-09-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}